n(2),n(2)-dimethylguanosine profile

N(2),N(2)-dimethylguanosine: elevated levels in urine of cancer patients [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N(2),N(2)-dimethylguanosine : A guanosine where the hydrogens of the amine group at C-2 are substituted by methyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	135501639
CHEBI ID	19289
SCHEMBL ID	40775
SCHEMBL ID	23648108
MeSH ID	M0053222

Synonym
guanosine, n,n-dimethyl-
CHEBI:19289
n,n-dimethylguanosine
2-(dimethylamino)-9-(beta-d-ribofuranosyl)-1,9-dihydro-6h-purin-6-one
2-dimethylamino-6-oxypurine riboside
2140-67-2
n2-dimethylguanosine
2,2-dimethylguanosine
n(2),n(2)-dimethylguanosine
m22g
9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-(dimethylamino)-3h-purin-6-one
p7nb8q3w0r ,
n2,n2-dimethylguanosine
unii-p7nb8q3w0r
AKOS016009587
9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-2-(dimethylamino)-1h-purin-6-one
dimethylguanosine
9-((2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-(dimethylamino)-1h-purin-6(9h)-one
SCHEMBL40775
2-dimethylguanosine
2-dimethylamino-6-oxypurineriboside
RSPURTUNRHNVGF-IOSLPCCCSA-N
2-(dimethylamino)guanosine
9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-(dimethylamino)-6,9-dihydro-3h-purin-6-one
n,n-dimethyl-guanosine
HY-113137
CS-0061838
9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-(dimethylamino)-1h-purin-6(9h)-one
mfcd00057049
2-(dimethylamino)-9-pentofuranosyl-9h-purin-6-ol
DTXSID90943957
Q27109160
n,n- dimethylguanosine
2-(dimethylamino)-9-((2r,3r,4s,5r)-5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolan-2-yl)-1h-purin-6-one
9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-(dimethylamino)-3,9-dihydro-6h-purin-6-one
9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-(dimethylamino)-1h-purin-6-one
C74036
9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-(dimethylamino)-6,9-dihydro-1h-purin-6-one
AS-57489
A848614
9-((2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-(dimethylamino)-1h-purin-6(9h)-one;2-dimethylamino-6-oxypurine riboside; n,n-dimethylguanosine; 2,2-dimethylguanosine;n,n-dimethylguanosine
SCHEMBL23648108
BP-58630

Role	Description
human metabolite	Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
methylguanosine	Any guanosine carrying one or more methyl substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	14 (46.67)	18.7374
1990's	6 (20.00)	18.2507
2000's	5 (16.67)	29.6817
2010's	3 (10.00)	24.3611
2020's	2 (6.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (3.33%)	5.53%
Reviews	1 (3.33%)	6.00%
Case Studies	1 (3.33%)	4.05%
Observational	0 (0.00%)	0.25%
Other	27 (90.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	2.04	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
hippuric acid hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591. N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl.	2.15	1	0	N-acylglycine	human blood serum metabolite; uremic toxin
homovanillic acid Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.	2.15	1	0	guaiacols; monocarboxylic acid	human metabolite; mouse metabolite
kynurenic acid Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.	2.15	1	0	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite
thymidine [no description available]	2.05	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
uridine [no description available]	3.47	8	0	uridines	drug metabolite; fundamental metabolite; human metabolite
cytidine [no description available]	2.47	2	0	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
aminoimidazole carboxamide Aminoimidazole Carboxamide: An imidazole derivative which is a metabolite of the antineoplastic agents BIC and DIC. By itself, or as the ribonucleotide, it is used as a condensation agent in the preparation of nucleosides and nucleotides. Compounded with orotic acid, it is used to treat liver diseases.. 5-aminoimidazole-4-carboxamide : An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.	2.03	1	0	aminoimidazole; monocarboxylic acid amide	mouse metabolite
citrulline citrulline : The parent compound of the citrulline class consisting of ornithine having a carbamoyl group at the N(5)-position.	2.15	1	0	amino acid zwitterion; citrulline	Daphnia magna metabolite; EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; protective agent; Saccharomyces cerevisiae metabolite
16-hydroxypalmitic acid 16-hydroxyhexadecanoic acid : An omega-hydroxy-long-chain fatty acid that is hexadecanoic acid (also known as palmitic acid) which is substituted at position 16 by a hydroxy group. It is a key monomer of cutin in the plant cuticle.	2.15	1	0	hydroxypalmitic acid; omega-hydroxy-long-chain fatty acid	plant metabolite
pseudouridine [no description available]	3.67	10	0	pseudouridines	fundamental metabolite
acadesine [no description available]	2.03	1	0	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor
1-methyladenosine [no description available]	3.09	5	0	methyladenosine	human metabolite
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	3.6	9	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
1,5-anhydroglucitol 1,5-anhydroglucitol: structure. 1,5-anhydro-D-glucitol : An anhydro sugar of D-glucitol.	2.15	1	0	anhydro sugar	human metabolite
homocitrulline L-homocitrulline : A L-lysine derivative that is L-lysine having a carbamoyl group at the N(6)-position. It is found in individuals with urea cycle disorders.	2.15	1	0	amino acid zwitterion; L-lysine derivative; non-proteinogenic L-alpha-amino acid; ureas	human metabolite; mouse metabolite
1-methylinosine 1-methylinosine : Inosine carrying a methyl substituent at position 1 on the hypoxanthine ring.	3.58	9	0	inosines	metabolite
5,6-dihydrouridine dihydrouridine : The uridine derivative obtained by formal hydrogenation of the endocyclic double bond in the uracil ring.	1.96	1	0	uridines	biomarker
1-methylguanosine 1-methylguanosine : Guanosine substituted with a methyl group at position N-1.	3.24	6	0	methylguanosine	metabolite
n-methyladenosine N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.	2	1	0	methyladenosine
2'-o-methyladenosine cordysinin B : A member of the class of adenosines that is adenosine in which the hydroxy group at position 2' is replaced by a methoxy group. It has been isolated from the mycelia of Cordyceps sinensis.	1.96	1	0	adenosines; ether	fungal metabolite
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	2.15	1	0
n(6)-(n-threonylcarbonyl)adenosine N(6)-(N-threonylcarbonyl)adenosine: anticodon adjacent nucleoside; occurs at3'end of anticodon in most tRNA's whih read codons beginning with adenosine;RN given refers to (L)-isomer. N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonine : An N-(adenosin-N(6)-ylcarbonyl)threonine in which the threonine portion has L-configuration.	2.01	1	0	L-threonine derivative; N-(adenosin-N(6)-ylcarbonyl)threonine	Escherichia coli metabolite; human metabolite
3-(3-amino-3-carboxypropyl)uridine 3-(3-amino-3-carboxypropyl)uridine: biosynthesized in E coli by novel enzyme which transfers 3-amino-3-carboxypropyl group into tRNA; enzyme requires S-adenosylmethione as donor cpd; structure. 3-(3-amino-3-carboxypropyl)uridine : A derivative of uridine, bearing an additional 3-amino-3-carboxypropyl substituent at position 5 on the uracil ring.	2.03	1	0	uridines
n(6),n(6)-dimethyladenosine N(6),N(6)-dimethyladenosine : A methyladenosine compound with two methyl groups attached to N(6) of the adenine nucleobase.	2	1	0	hydrocarbyladenosine
ribosylimidazole acetic acid ribosylimidazole acetic acid: metabolite of imidazole acetic acid	2.03	1	0	1-ribosylimidazole
ribothymidine ribothymidine : A methyluridine having a single methyl substituent at the 5-position on the uracil ring.	2.03	1	0	methyluridine	antigen; Escherichia coli metabolite; human metabolite
ribose ribopyranose : The pyranose form of ribose.	2.03	1	0	D-ribose; ribopyranose
isoguanosine [no description available]	2.03	1	0
3-methylcytidine [no description available]	2.31	1	0	methylcytidine
s-adenosylmethionine (R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine.	3.51	2	0	organic cation; sulfonium compound	coenzyme; cofactor; human metabolite; micronutrient; Mycoplasma genitalium metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
5-hydroxymethyl-2'-deoxyuridine 5-hydroxymethyl-2'-deoxyuridine : A pyrimidine 2'-deoxyribonucleoside composed of 2'-deoxyuridine having a 5-hydroxymethyl substituent.	2.05	1	0
n6-methyl-n6-threonylcarbamoyladenosine N6-methyl-N6-threonylcarbamoyladenosine: structure in first source	2.03	1	0
3-methyluridine 3-methyluridine: isolated from normal human urine & is a minor constituent of tRNA form yeast, rat and human liver; structure	2.38	2	0
deoxyguanosine [no description available]	2.05	1	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanine [no description available]	2.66	3	0	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose.	7.17	29	1	guanosines; purines D-ribonucleoside	fundamental metabolite
inosine [no description available]	3.67	10	0	inosines; purines D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
7-methylguanine 7-methylguanine: RN given refers to unlabeled cpd; structure. 7-methylguanine : A methylguanine that is guanine substituted by a methyl group at position 7. It is a metabolite obtained during the methylation of DNA.. 2-imino-7-methyl-1,2,3,7-tetrahydro-6H-purin-6-one : A 7-methylguanine that is 1,2,3,7-tetrahydro-6H-purin-6-one substituted by an imino group at position 2 and a methyl group at position 7.. 2-amino-7-methyl-7H-purin-6-ol : A 7-methylguanine that is 7H-purine substituted by an amino group at position 2, a methyl group at position 7 and a hydroxy group at position 6.. 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one : A 7-methylguanine that is 1,7-dihydro-6H-purin-6-one substituted by an amino group at position 2 and a methyl group at position 7.	2.66	3	0	7-methylguanine
2'-o-methylguanosine 2'-O-methylguanosine : Guanosine with the hydrogen on the hydroxyl at position C-2' substituted with a methyl group.	2.38	2	0	methylguanosine	metabolite
8-hydroxy-2'-deoxyguanosine 8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.	2.05	1	0	guanosines	biomarker
7-methylguanosine 7-methylguanosine : A positively charged methylguanosine in which a single methyl substituent is located at position 7.	2.06	1	0	methylguanosine; organic cation	metabolite
8-methylguanosine 8-methylguanosine: structure in first source	1.96	1	0

Condition	Relationship Strength	Studies	Trials
Nervous System Disorders [description not available]	2.6	1	0
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	2.6	1	0
Chronic Kidney Diseases [description not available]	2.15	1	0
Bright Disease A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.	2.15	1	0
Kidney, Polycystic [description not available]	2.15	1	0
Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.	2.15	1	0
Polycystic Kidney Diseases Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.	2.15	1	0
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	2.15	1	0
Breast Cancer [description not available]	2.89	4	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.89	4	0
Leukemia, Lymphocytic [description not available]	2.36	2	0
Acute Myelogenous Leukemia [description not available]	1.96	1	0
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	2.36	2	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	1.96	1	0
Granulocytic Leukemia [description not available]	1.96	1	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	1.96	1	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	1.96	1	0
Pneumonia Infection of the lung often accompanied by inflammation.	1.96	1	0
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	1.96	1	0
Anorexia Nervosa An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)	1.96	1	0
Lymph Node Metastasis [description not available]	1.95	1	0
Metastase [description not available]	1.95	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	1.95	1	0
Benign Neoplasms [description not available]	2.65	3	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.65	3	0
Chronic Kidney Failure [description not available]	3.38	1	1
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	3.38	1	1
Leucocythaemia [description not available]	1.95	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	1.95	1	0
Infant, Small for Gestational Age An infant having a birth weight lower than expected for its gestational age.	1.96	1	0

n(2),n(2)-dimethylguanosine

Description

Cross-References

Synonyms (43)

Roles (1)

Drug Classes (1)

Research

Studies (30)

Study Types